TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

There was an interesting trend in intrahepatic cholangiocarcinoma tumors whereby patients with upregulation of CEBPA RNA 24 h after drug administration appeared more likely to have a response or disease stabilization, and we saw higher disease control rates in this subgroup (disease control rate by RECIST = 80%).

also in 951 other papers